NCT02719691: Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

NCT02719691
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 101 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Only patients with TNBC will be eligible for the expansion cohort
Exclusions: 
https://ClinicalTrials.gov/show/NCT02719691

Comments are closed.

Up ↑